Newsletter – May 2024 – Biotech Fund
Equities returned to winning ways in May following a negative month. Read more.
READ MORENewsletter – April 2024 – Biotech Fund
The equity market stumbled in April with the S&P 500 decreasing by 4.1%, breaking its streak of five consecutive positive months. Read more.
READ MORENewsletter – March 2024 – Biotech Fund
The Merchant Biotech Fund retreated a little this month finishing the month at $1.3940. Read more.
READ MORENewsletter – February 2024 – Biotech Fund
The month of February was a strong month for the Merchant Biotech Fund (Fund or MBF) finishing up 16.71%. Read more.
READ MORENewsletter – January 2024 – Biotech Fund
The Merchant Biotech Fund (MBF or Fund) started the 2024 calendar year well, finishing up 11.12% for the month of January. Read more.
READ MORENewsletter – December 2023 – Biotech Fund
Closing out the year the Merchant Biotech Fund finished up strongly. Read more.
READ MORENewsletter – November 2023 – Biotech Fund
The Merchant Biotech Fund (MBF or Fund) had a strong month in November, finishing at $1.0058. Read more.
READ MORENewsletter – September 2023 – Biotech Fund
The general market softened into September and the biotech sector held its ground. Read more.
READ MORENewsletter – July 2023 – Biotech Fund
At the end of July, it appeared the Australian inflation rate was softening with monthly CPI hitting a 16-month low. Read more.
READ MORENewsletter – June 2023 – Biotech Fund
The Merchant Biotech Fund finished up 43.25% for the financial year. Read more.
READ MORENewsletter – April 2023 – Biotech Fund
The Merchant Biotech Fund (“MBF” or “the Fund”) is up 59% for the financial year vs the ASX Healthcare 300 Index (XHK) up 6.09% over the same period. Read more.
READ MORENewsletter – March 2023 – Biotech Fund
The Merchant Biotech Fund closed up 5.5% for the month. Read more.
READ MORENewsletter – February 2023 – Biotech Fund
Global equities declined in February after a strong January. Merchant Biotech Fund (MBF or Fund) retreated a little to finish the month $0.7691.Read more.
READ MORENewsletter – January 2023 – Biotech Fund
A solid January could be a good sign for the market and potentially foreshadow a continued uptick in the months that follow. Read more.
READ MORENewsletter – December 2022 – Biotech Fund
The Merchant Biotech Fund (MBF) finished December up 29.34% for the Financial Year. Read more.
READ MORENewsletter – November 2022 – Biotech Fund
November started on a sombre note amid the Fed’s rate hike and better-than-expected job numbers. Read more.
READ MORENewsletter – October 2022 – Biotech Fund
Global equity markets rounded the month out higher after a brutal September slump. In the US the Dow ended October with a gain of +13.96%, its best monthly advance since January 1976 and its 10th best month of the last century. Read more.
READ MORENewsletter – September 2022 – Biotech Fund
This month the bear market intensified, with the S&P 500 joining the Dow Jones in undercutting their June lows and the Nasdaq composite sitting just above that level. Read more.
READ MORENewsletter – August 2022 – Biotech Fund
The question we wanted answered in July was “can the rally last?” August provided the answer. Read more.
READ MORENewsletter – July 2022 – Biotech Fund
At the closing bell on the last trading day of the Financial Year, the ASX Biotech Sector was down approximately 40% for the full Financial Year. Read more.
READ MORENewsletter – May 2022 – Biotech Fund
Against the ASX & US Listed Biotech Indexes we are faring better but at the moment it’s all a little painful. Read more.
READ MORENewsletter – April 2022 – Biotech Fund
April brought another volatile month on the stock market. The release of inflation numbers and a rise in interest rates both globally and domestically led to a shakeout. Read more.
READ MORENewsletter – March 2022 – Biotech Fund
As the dust settles on the month of March 2022 for the Merchant Biotech Fund increasing inflation and the Russian war in Ukraine continue to plague the technology/healthcare sector. Read more.
READ MOREBrook Corte Money News Interview with Andrew Chapman
Biotech companies are at the centre of future success, with one investment group setting its sights on the industry. These are the companies working to help us live longer, healthier lives by creating cutting edge treatments for devastating diseases. Merchant Funds’ new Biotech fund focuses on emerging Australian biotech, medical and health sciences companies, giving […]
READ MORENewsletter – February 2022 – Biotech Fund
The Merchant Biotech Fund continued to suffer during February with the Biotechnology and Technology sectors both being hardest hit as a result of the Russian invasion of Ukraine.
READ MORENewsletter – January 2022 – Biotech Fund
Auspiciously January 2022 will go down as the first month investing for the Merchant Biotech Fund.
READ MORE